Evicenter
P&T meetings

Ivonescimab

EGFR-mutated non-small-cell lung cancer

Launch
Not announced
Last updated
79 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

EGFR tyrosine kinase inhibitors

1 evidence topic · 2 sources

First-line therapy for classical activating EGFR mutations

“third-generation EGFR TKIs, such as osimertinib, should be the preferred first-line option” (opens the source at this quote in a new tab)